" Aducanumab is an anti-body given to patients through an intravenous infusion. This antibody, in high dosages, goes into the brain and binds to a toxic protein called amyloid. Amyloid is a necessary part in the development of Alzheimer’s, triggering other proteins like tau, etc. Aducanumab works to draw amyloid out which can slow down the disease. We don’t specifically know how much amyloid needs to be removed, but now we have a drug that can substantially remove early amyloid plaques. This kind of drug is a disease modifying drug opposed to a drug that just treats Alzheimer symptoms. "
We are glad you have chosen to leave a comment. Please keep in mind that comments are moderated according to our comment policy.